Obesity drugmaker Novo Nordisk picks Maziar Mike Doustdar as new CEO
Novo Nordisk has a new CEO. Maziar Mike Doustdar takes the helm. This follows the departure of Lars Fruergaard Jorgensen. The company aims to boost sales. It also wants to improve its share price. Novo Nordisk faces competition from Eli Lilly in t...
By Reuters |
Reuters
Novo Nordisk named Maziar Mike Doustdar as CEO on Tuesday as the Wegovy maker seeks to revive sales and its share price, hit by worries it is losing the obesity drug race it started to U.S. rival Eli Lilly.
The appointment comes after the abrupt removal in May of CEO Lars Fruergaard Jorgensen by Novo and the Novo Nordisk Foundation - the Danish company's controlling shareholder.
The appointment comes after the abrupt removal in May of CEO Lars Fruergaard Jorgensen by Novo and the Novo Nordisk Foundation - the Danish company's controlling shareholder.
Download
The Economic Times Business News App for the Latest News in Business, Sensex, Stock Market Updates & More.
The Economic Times Business News App for the Latest News in Business, Sensex, Stock Market Updates & More.
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
Related Articles
Pfizer closes in on $7.3 billion takeover of anti-obesity drugmaker Metsera: ReportADVERTISEMENT
